CompanyGraph
Consun Pharmaceutical Group Limited
1681 · HKEX · China
Price data from its C1P listing on FSX, quoted in EUR
chinaconsun.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.59B, above the global median of $1.15B
- FinancialsAltman Z-Score 6.7: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
6.04%Below 5Y avg (6.49%)
Annual Rate
HKD 0.80Paid semi-annual
Payout Ratio
45.6%Sustainable
Payback Period
2.0 yr
Last Ex-Dividend
Jun 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.48BHKD1.59B · vs all stocks (USD)
Trailing P/E
9.07xRevenue (TTM)
3.98BCNY507.03M · vs all stocks (USD)
Profit Margin
31.55%Beta
0.4800xvs all stocks
52-Week Change
-4.86%vs all stocks
Forward Annual Dividend Yield
6.04%vs all stocks
Market Capitalization
12.48BHKD1.59B · vs all stocks (USD)
Enterprise Value
9.09BHKD1.16B · vs all stocks (USD)
Trailing P/E
9.07xForward P/E
7.07xPrice to Sales (TTM)
3.27xPrice to Book (MRQ)
2.12xEnterprise to Revenue
2.29xEnterprise to EBITDA
6.47xProfit Margin
31.55%Operating Margin
34.47%Return on Assets (TTM)
11.74%Return on Equity (TTM)
23.60%Revenue (TTM)
3.98BCNY507.03M · vs all stocks (USD)
Revenue per Share (TTM)
4.03CNYUpdated Aug 19, 2026Quarterly Revenue Growth
8.80%Gross Profit (TTM)
3.10BCNY395.72M · vs all stocks (USD)
EBITDA (TTM)
1.26BCNY161.25M · vs all stocks (USD)
Net Income (TTM)
1.25BCNY159.95M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.50%Operating Cash Flow (TTM)
1.41BCNY179.79M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-242.39MCNY-30.90M · vs all stocks (USD)
Forward Annual Dividend Rate
0.8000HKDUpdated Aug 19, 2026Forward Annual Dividend Yield
6.04%vs all stocks
Trailing Annual Dividend Rate
0.7300HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
5.51%vs all stocks
5-Year Average Dividend Yield
6.49%vs all stocks
Payout Ratio
45.64%Minority Interest (Equity)
302.84MCNYFY2025 · Dec 31, 2025Revenue
3.42BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
750.24MCNYFY2025 · Dec 31, 2025Gross Profit
2.67BCNYFY2025 · Dec 31, 2025Operating Income
1.15BCNY170.90M · vs all stocks (USD)
Pre-tax Income
1.20BCNYFY2025 · Dec 31, 2025Income Tax Expense
107.29MCNYFY2025 · Dec 31, 2025Net Income
1.09BCNYFY2025 · Dec 31, 2025EBIT
1.20BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.26BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.52BCNYFY2025 · Dec 31, 2025Non-operating Interest Income
85.28MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
4.36MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.27CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.26CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
848.01MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
848.01MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
-11.06MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.08BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.01BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.23BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.20BCNYFY2025 · Dec 31, 2025Other Non-cash Items
-80.92MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.51MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-18.52MCNYFY2025 · Dec 31, 2025Capital Expenditures
-68.48MCNYFY2025 · Dec 31, 2025Net Acquisitions
-25.00MCNYFY2025 · Dec 31, 2025Purchase of Investments
-5.65BCNYFY2025 · Dec 31, 2025Sale of Investments
3.54BCNYFY2025 · Dec 31, 2025Other Investing Activity
-8.05MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.22BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-275.47MCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-52.41MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-168.02MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-498.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-978.27MCNYFY2025 · Dec 31, 2025Shares Outstanding
840.11MSharesUpdated Aug 19, 2026Float Shares
456.90MSharesUpdated Aug 19, 2026% Held by Insiders
45.64%vs all stocks
% Held by Institutions
22.70%vs all stocks
Total Cash (MRQ)
4.54BCNY579.16M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.65CNYUpdated Aug 19, 2026Total Debt (MRQ)
247.79MCNY31.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0440xCurrent Ratio (MRQ)
3.22xBook Value per Share (MRQ)
6.28CNYUpdated Aug 19, 2026Total Assets
6.41BCNY950.61M · vs all stocks (USD)
Total Current Assets
4.60BCNYFY2025 · Dec 31, 2025Total Liabilities
1.57BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.81BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
141.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.43BCNYFY2025 · Dec 31, 2025Cash
1.23BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.23BCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.67BCNYFY2025 · Dec 31, 2025Accounts Receivable
251.32MCNYFY2025 · Dec 31, 2025Inventory
271.40MCNYFY2025 · Dec 31, 2025Accounts Payable
130.50MCNYFY2025 · Dec 31, 2025Short-term Debt
209.71MCNYFY2025 · Dec 31, 2025Long-term Debt
3.21MCNYFY2025 · Dec 31, 2025Common Stock (Book)
67.23MCNYFY2025 · Dec 31, 2025Retained Earnings
3.99BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.84BCNY717.46M · vs all stocks (USD)
52-Week Low
12.31HKDUpdated Aug 19, 202652-Week High
19.35HKDUpdated Aug 19, 202652-Week Change
-4.86%vs all stocks
Beta
0.4800xvs all stocks
50-Day MA
13.54HKDUpdated Aug 19, 2026200-Day MA
15.52HKDUpdated Aug 19, 2026Avg 10-Day Volume
1.17MSharesUpdated Aug 19, 2026Avg 30-Day Volume
1.11MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
1.47CNYUpdated Aug 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.7: safe zoneNotable
Altman Z-Score: 6.70
High earnings qualityNotable
Earnings Quality Score: 0.54
High structural barrier to entryNotable
Barrier to Entry: 0.56
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.59B, above the global median of $1.15BNotable
Market cap (USD): 1,591,545,945.988Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Intellia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inner Mongolia Furui Medical Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Indian Railway Catering and Tourism Corporation Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Classys Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Pharma Research Products Co., Ltd
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth